Compare SHOO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | NUVB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 1993 | N/A |
| Metric | SHOO | NUVB |
|---|---|---|
| Price | $43.03 | $9.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $41.00 | $10.63 |
| AVG Volume (30 Days) | 960.3K | ★ 6.0M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $2,362,727,000.00 | $26,748,000.00 |
| Revenue This Year | $13.10 | $609.55 |
| Revenue Next Year | $11.74 | $197.91 |
| P/E Ratio | $55.13 | ★ N/A |
| Revenue Growth | 6.41 | ★ 1137.19 |
| 52 Week Low | $19.05 | $1.54 |
| 52 Week High | $44.99 | $9.75 |
| Indicator | SHOO | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 63.57 |
| Support Level | $42.45 | $9.06 |
| Resistance Level | $43.90 | $9.75 |
| Average True Range (ATR) | 1.03 | 0.46 |
| MACD | -0.35 | -0.05 |
| Stochastic Oscillator | 22.27 | 65.13 |
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.